Here we synthesized RCT and RWE data, and the evidence largely supported the preservation of quality of life with the addition of the CDK4/6i, palbociclib, to endocrine therapy in patients with HR+/HER2- aBC or mBC. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.